Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
| Autor: | Manel Vera, Anna Saurina, Albert Botey, Francisco Cervantes, Manel Solé, Mónica Pou, Nuria Saval |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Gastroenterology Piperazines Myelogenous Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans Enzyme Inhibitors neoplasms Acute tubular necrosis business.industry Acute kidney injury Myeloid leukemia Imatinib Hematology Acute Kidney Injury Middle Aged Protein-Tyrosine Kinases medicine.disease Leukemia Pyrimidines Imatinib mesylate Endocrinology Oncology Benzamides Imatinib Mesylate Female Hemodialysis business medicine.drug |
| Zdroj: | Leukemia & Lymphoma. 44:1239-1241 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | A 58-year-old woman with chronic myeloid leukemia (CML), and previous intolerance to interferon was treated with the BCR-ABL tyrosine kinase protein inhibitor imatinib mesylate. Coincidentally, with the start of treatment, the patient developed acute renal failure, with acute tubular necrosis being observed on histopathology. Imatinib was stopped and three hemodialysis sessions were performed, which was followed by a progressive improvement of the renal function and normalization of the urine output. One year later the patient still has mild chronic renal failure and remains in chronic phase of CML on hydroxyurea treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|